Last edition
News about "Shilpa Medicare"
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Shilpa Medicare | 07/04/2025 | By Aishwarya
Shilpa Medicare Gets SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets
Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets.
Shilpa Medicare | 12/03/2025 | By Aishwarya | 228
Shilpa Medicare Launches ORAAL for the Treatment of Oral Mucositis
ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association.
Shilpa Medicare | 16/10/2023 | By Manvi | 460
Shilpa Medicare gets two minor observations from US FDA at Hyderabad facility
The observations were noticed at Unit VII, Analytical Services Division
Shilpa Medicare | 13/03/2023 | By Sudeep Soparkar | 797
Shilpa Medicare registers Bengaluru facility with Ministry of Health, UAE
The facility is involved in the manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems
Shilpa Medicare | 20/02/2023 | By Sudeep Soparkar | 710
Shilpa Medicare's Telangana facility bags Health Canada GMP approval
The facility is involved in the manufacturing, packaging, labelling and testing of finished dosage forms
Shilpa Medicare | 01/12/2022 | By Sudeep Soparkar | 378
Shilpa Medicare's plant in Telangana bags US FDA clearance
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited (Parent Organization) and its agreed parties
Shilpa Medicare | 23/09/2022 | By Sudeep Soparkar | 557
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy